Relationship between ambient air pollution and DNA damage in Polish mothers and newborns

Environmental Health Perspectives

Volumn 106, Issue SUPPL. 3, 1998, Pages 821-826

  Whyatt, Robin M ^a   Santella, Regina M ^a   Jedrychowski, Wieslaw ^b   Garte, Seymour J ^c   Bell, Douglas A ^d   Ottman, Ruth ^e   Gladek Yarborough, Alicja ^a   Cosma, Greg ^f   Young, Tie Lan ^a   Cooper, Thomas B ^e   Randall, Mary C ^a   Manchester, David K ^g   Perera, Frederica P ^a,h  

^a Columbia Univ Sch of Public Health ^*  (United States)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f Department of Environmental and Radiological Health Sciences   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h Affiliated Faculty Global Institute of Public Health   (United States)

Author keywords

Air pollution; Cigarette smoking; CYP1A1 MspI RFLP; GSTM1; Newborns; PAH DNA adducts; Poland

Indexed keywords

CYTOCHROME P450; GLUTATHIONE TRANSFERASE; POLYCYCLIC AROMATIC HYDROCARBON;

ADULT; AIR POLLUTION; AMBIENT AIR; CIGARETTE SMOKING; CONFERENCE PAPER; DNA ADDUCT; DNA DAMAGE; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; MOTHER; NEWBORN; POLAND; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UMBILICAL CORD BLOOD;

EID: 0031828468     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106821     Document Type: Conference Paper

References (71)

1. Perera FP, Hemminki K, Grzybowska E, Morykicwicz G, Michalska J, Santella RM, Young TL, Dickey C, Brandt-Rauf P, DeVivo I, et al. Molecular and genetic damage from environmental pollution in Poland. Nature 360:256-258 (1992).
2. Jedrychowski W, Becher H, Wahrendorf J, Basa-Cierpialek Z. A case-control study of lung cancer with special reference to the effect of air pollution in Poland. J Epidemiol Community Health 44:114-120 (1990).
3. Whyatt RM, Garte SJ, Cosma G, Bell DA, Jedrychowski W, Wahrendorf J, Randall MC, Cooper TB, Ottman R, Tang D et al. CYP1A1 messenger RNA levels in placental tissue as a biomarker of environmental exposure. Cancer Epidemiol Biomarkers Prev 4:147-153 (1995).
4. Srivastava VK, Chauhan SS, Srivastava PK, Kumar V, Misra UK. Fetal translocation and metabolism of PAH obtained from coal fly ash given intratracheally to pregnant rats. J Toxicol Environ Health 18:459-469 (1986).
5. Nebert D, Tapken S. Transfer of benzo(a)pyrene into mouse embryos and fetuses. Arch Toxicol 35:2943-2953 (1988).
6. Simconova M, Georgieva V, Alexiev C. Cytogenetic investigations of human subjects occupationally exposed to chemicals from the petroleum-processing industry. Environ Res 48:145-153 (1989).
7. Bui QQ, Tran MB, West WL. A comparative study of the reproductive effects of methadone and benzo(a)pyrenc in the pregnant and pseudopregnant rat. Toxicology 42:195-204 (1986).
8. Shum S, Jensen NM, Nebert DW. The murine Ah locus: in utero toxicity and teratogenesis associated with genetic differences and benzo(a)pyrene metabolism. Teratology 20:365-376 (1979).
9. York RG, Manson JM. Neonatal toxicity in mice associated with the Ahb allele following transplacental exposure to 3-methylcholanthrene. Toxicol Appl Pharmacol 72:417-426 (1984).
10. Bulay OM, Wattemberg LW. Carcinogenic effects of polycyclic hydrocarbon carcinogens administrated to mice during pregnancy on the progeny. JNCI 46:397-402 (1971).
11. Nikonova TV. Transplacental action of benzo(a)pyrene and pyrene. Bull Exp Biol Med 84:1025-1027 (1977).
12. Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. JNCI 88:496-509 (1996).
13. Harris C. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 51 (Suppl): 5023S-5044S (1991).
14. Shamsuddin AKM, Gan R. Immunocytochemical localization of benzo(a)pyrene-DNA adducts in human tissue. Hum Pathol 19:309-315 (1988).
15. Lewtas J, Mumford J, Everson RB, Hulka B, Wilcosky T, Kozumbo W, Thompson C, George M, Dobiáa SR, Li X, et al. Comparison of DNA adducts from exposure to complex mixtures in various human tissues and experimental systems. Environ Health Perspect 99:89-97 (1993).
16. Tang D, Santella RM, Blackwood A, Young TL, Mayer J, Jaretzki A, Grantham S, Carberry D, Steinglass KM, Tsai WY, et al. A case-control molecular epidemiologic study of lung cancer. Cancer Epidemiol Biomarkers Prev 4:341-346 (1995).
17. Bartsch H, Terracini B, Malaveille C. Quantitative comparisons of carcinogenicity, mutagenicity and electrophilicity of 10 direct-acting alkylating agents and the initial 06-alkylguanine ratio in DNA with carcinogenic potency in rodents. Mutat Res 110:181-219 (1983).
18. Lutz WK. Quantitative evaluation of DNA binding data for risk estimation and for classification of direct and indirect carcinogens. J Cancer Res Clin Oncol 112:85-91 (1986).
19. Poirier MC, Beland FA. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models: implications for DNA adduct-based human cancer risk assessment. Chem Res Toxicol 5:749-755 (1992).
20. Perera HP, Whyatt RM, Jedrychowski W, Rauh V, Manchester D, Santella RM, Ottman R. Recent developments in molecular epidemiology: a study of the effects of environmental polycyclic aromatic hydrocarbons on birth outcomes in Poland. Am J Epidemiol 147:309-314 (1998).
21. Binková B, Lewtas J, Misková I, Rössner P, Cerna M, Mrácková G, Peterková K, Mumford J, Meyer S, Srám R. Biomarkcr studies in the Northern Bohemia. Environ Health Perspect 104(Suppl 3):591-597 (1996).
22. Nebert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res 247:267-281 (1991).
23. Pasanen M, Pelkonen O. The expression and environmental regulation of P450 enzymes in human placenta. Crit Rev Toxicol 24:211-229 (1994).
24. Amos CI, Caporaso NE, Weston A. Host factors in lung cancer risk: a review of interdisciplinary studies. Cancer Epidemiol Biomarkers Prev 1:505-513 (1991).
25. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501Aa gene. FEBS Lett 263:131-133 (1990).
26. Hayashi SI, Watanabe J, Nakachi K. Cenetic linkage of lung cancer-associated MspI polymorphism with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J Biochem 110:407-411 (1991).
27. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H. Point-mutational MspI and Ile-Val polymorphism closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1:1485-1489 (1992).
28. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, Borresen A-L. Human CYP1A1 (cytochrome P450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1:20-25 (1991).
29. Shields PC, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trump BF, Hoover RN, Weston A, Harris CC. Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 2:481-85 (1993).
30. Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 15:1785-1790 (1994).
31. Sugimura H, Hamada GS, Suzuki I, Iwase T, Kiyokawa E, Kino I, Tsugane S. CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil. Pharmacogenetics 5(Spec No):145-148 (1995).
32. Bell DA, Thompson CL, Taylor J, Clark G, Miller CR, Perera F, Hsieh L, Lucien GW. Genetic monitoring of human polymorphic cancer susceptibility genes by polymcrase chain reaction: application to glutathione transferase. Environ Health Perspect 98:113-117 (1992).
33. McWilliams JE, Sanderson BJS, Harris EL, Richert-Boc KE, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 4:589-594 (1995).
34. Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) of glutathione transferase (class mu) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis 11(1):33-26 (1990).
35. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotype of P4501A1 and mu-class glutachione S-transferase genes. Jpn J Cancer Res 83:866-870 (1992).
36. Zhong S, Howie AH, Ketterer B, Taylor J, Hayes JD, Beckett GJ, Wathen CG, Wolf CR, Spurr NK. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 9:1533-1537(1991).
37. Brockmöller J, Kerb R, Drakoulis N, Niez M, Roots I. Genotype and phenotype of glutathione 5-transferase class μ isoenzymes μ and O in lung cancer patients and controls. Cancer Res 53:1004-1011 (1993).
38. Nazar-Stewart V, Motulsky AG, Eaton DL, White E, Hornung SK, Zhong-Tai L., Srapleton P, Weiss NS. The glutathione S- transferase μ polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 53(May 15):2313-2318 (1993).
39. Ichiba M, Hagmar L, Rannug A, Högstedt B, Alexandrie A-K, Carstensen U, Hemminki K. Aromatic DNA adducts, micronuclei and genetic polymorphism for CYP1A1 and GST in chimneysweeps. Carcinogencsis 15:1347-1.352 (1994).
40. Rothman N, Shields PC, Poirier MC, Harrington AM, Ford DP, Strickland PT. The impact of glucathione 5-transferase M1 and cytochrome P450 1A1 genotypes on white blood cell polycyclic aromatic hydrocarbon-DNA adduct levels in humans. Mol Carcinogenesis 14:63-68 (1995).
41. Shields PG, Bowman ED, Harrington AM, Doan VT, Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res 53:3486-3492 (1993).
42. Mooney LA, Bell DA, Santella RM, Van Bennekum AM, Ottman R, Paik M, Blaner WS, Lucier GW, Covey L, Young TL, et al. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 18:503-509 (1997).
43. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogcn-DNA adduct levels mediated by genetic polymorphisms in vivo. JNCI 87:902-907 (1995).
44. Robertson IG, Guthenberg C, Mannervik B, Jernstrom B. Differences in stereoselectivity and catalytic efficiency of three human glutathione transferases in the conjugation of glutathione with 7 beta, 8 alpha-dihydroxy-9 alpha, 10 alpha-oxy-7,8,9,10- tetrahydrobenzo(a)pyrene. Cancer Res 46:2220-2224 (1986).
45. Perera FP, Hemminki K, Young TL, Brenner D, Kelly G, Santella RM. Detection of polycyclic aromatic hydrocarbon- DNA adducts in white blood cells of foundry workers. Cancer Res 48:2288-2291 (1988).
46. Samella RM, Gasparro FP, Hsieh LL. Quantitation of carcinogen-DNA adducts with monoclonal antibodies. Prog Exp Tumor Res 31:63-75 (1987).
47. Manchester DK, Parker NB, Bowman CM. Maternal smoking increases xenobiotic metabolism in placenta but not umbilical vein endothelium. Pediatric Res 18:1071-1075 (1984).
48. Manchester D, Jacoby E. Decreased placental monooxygenase activities associated with birth defects. Teratology 30:31-37 (1984).
49. van Schooten HJ, van Leeuwen FE, Hillebrand MJX, deRijke ME, Hart AAM, van Veen HG, Oosterink S, Kriek E. Determination of benzo(a)pyrene diol epoxidc-DNA adducts in white blood cell DNA from coke-oven workers: the impact of smoking. JNCI 882:9227-9233 (1990).
50. Mooney LA, Santella RM, Covey L, Jeffrey AM, Bigbee W, Randall MC, Cooper TB, Ottman R, Tsai W-Y, Wazneh L, et al. Decline in DNA damage and other biomarkers in peripheral blood following smoking cessation. Cancer Epidemiol Biomarkers Prev 4:627-634 (1995).
51. Perera FP, Santella RM, Brenner D, Poirier MC, Munshi AA, Fischman HK, Van Ryzin J. DNA adducts, protein adducts and sister chromatid exchange in cigarette smokers and nonsmokers. JNCI 79:449-456 (1987).
52. Everson RB, Randerath E, Santella R, Avitts TA, Weinstein IB, Randerath K. Quantitative associations between DNA damage in human placenta, maternal smoking, and birth weight. JNCI 80:567-576 (1988).
53. 32P-postlabeling procedure. Environ Health Perspect 99:229-231 (1993).
54. Gallagher JE, Everson RB, Lewtas J, George M, Lucier GW. Comparison of DNA adduct levels in human placenta from polychlorinated biphenyl exposed women and smokers in which CYP1A1 levels are similarly elevated. Teratog Carcinog Mutagen 14:183-192 (1994).
55. Manchester DK, Bowman ED, Parker NB, Caporaso NE, Weston A. Determinants of polycyclic aromatic hydrocarbon-DNA adducts in human placenta. Cancer Res 52:1499-1503 (1992).
56. Sanyal KM, Li YL, Belanger K. Metabolism of polynuclear aromatic hydrocarbon in human term placenta influenced by cigarette smoke exposure. Reprod Toxicol 8:411-418 (1994).
57. 32P-postlabelling analysis of DNA adducts in monocytes of smokers and passive smokers. Int Arch Occup Environ Health 62:299-303 (1990).
58. Scherer G, Conze C, Tricker AR, Adlkofer F. Uptake of tobacco smoke constituents on exposure to environmental tobacco smoke (ETS). Clin Invest 70:352-367 (1992).
59. Sorsa M, Husgafvel-Pursianen K, Jarventaus H, Koskimies K, Salo H, Vainio H. Cytogenetic effects of tobacco smoke exposure among involuntary smokers. Mutat Res 222:111-116 (1989).
60. Gorgels WJMJ, Van Poppel G, Jarvis MJ, Stenhuis W, Kok FJ. Passive smoking and sister-chromatid exchanges in lymphocytes. Mutat Res 279:233-238 (1992).
61. Crawford FG, Mayer J, Santella RM, Cooper T, Ottman R, Tsai WY, Simon-Cereijido G, Wang M, Tang D, Perera FP. Biomarkers of environmental tobacco smoke in preschool children and their mothers. JNCI 86:1398-1402 (1994).
62. Becher H, Zatonski W, Jöckel K-H. Passive smoking in Germany and Poland: comparison of exposure levels, sources of exposure, validity, and perception. Epidemiology 3:509-514 (1992).
63. Calabrese EJ. Age and Susceptibility to Toxic Substances. New York:John Wiley & Sons, 1986.
64. National Research Council, National Academy of Sciences. Pesticides in the Diets of Infants and Children. Washington: National Academy Press, 1993.
65. Laib RJ, Klein KP, Bolt HM. The rat liver foci bioassay: age dependence of induction by vinyl chloride of ATP-deficient foci. Carcinogencsis 6:65-68 (1985).
66. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280 (1996).
67. Perera FP. Environment and cancer: who are susceptible? Science 278:1068-1073 (1997).
68. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15:2961-2963 (1994).
69. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 14:77-87 (1993).
70. Persson I, Johansson I, Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res 231:227-230 (1997).
71. Whyatt RM, Hemminki K, Santella RM, Hou Y, Perera FP. In preparation.